Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Outcomes in COVID-19 metformin studies
Outcomes in metformin studies. Studies to date are mostly with diabetic patients.
00.250.50.7511.251.51.752+Reis (DB RCT)-15%1.15 [0.73-1.83]hosp./ER32/21727/206Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-15%1.15 [0.73-1.83]32/21727/206-15% improvementLuo75%0.25 [0.07-0.84]death3/10422/179Improvement, RR [CI]TreatmentControlWang58%0.42 [0.01-1.98]death1/913/49Chen33%0.67 [0.20-1.78]death4/4315/77Bramante7%0.93 [0.81-1.06]death394/2,333791/3,923Crouse61%0.39 [0.16-0.87]death8/7634/144Wander15%0.85 [0.80-0.90]deathTau​2 = 0.01; I​2 = 56.6%PrEP17%0.83 [0.71-0.97]410/2,565875/4,37217% improvementAll studies15%0.85 [0.73-0.99]442/2,782902/4,57815% improvement7 metformin COVID-19 studiesc19early.com/mf Oct 16, 2021Tau​2 = 0.01; I​2 = 53.7%; Z = 2.13Effect extraction pre-specifiedFavors metforminFavors control 00.250.50.7511.251.51.752+Luo75%0.25 [0.07-0.84]3/10422/179Improvement, RR [CI]TreatmentControlWang58%0.42 [0.01-1.98]1/913/49Chen33%0.67 [0.20-1.78]4/4315/77Bramante7%0.93 [0.81-1.06]394/2,333791/3,923Crouse61%0.39 [0.16-0.87]8/7634/144Wander15%0.85 [0.80-0.90]Tau​2 = 0.01; I​2 = 56.6%PrEP17%0.83 [0.71-0.97]410/2,565875/4,37217% improvementAll studies17%0.83 [0.71-0.97]410/2,565875/4,37217% improvement6 metformin COVID-19 mortality resultsc19early.com/mf Oct 16, 2021Tau​2 = 0.01; I​2 = 56.6%; Z = 2.38Favors metforminFavors control 00.250.50.7511.251.51.752+Wander2%0.98 [0.92-1.06]Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP2%0.98 [0.92-1.06]2% improvementAll studies2%0.98 [0.92-1.05]2% improvement1 metformin COVID-19 ICU resultc19early.com/mf Oct 16, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.56Favors metforminFavors control 00.250.50.7511.251.51.752+Wander3%0.97 [0.94-1.01]hosp.Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP3%0.97 [0.94-1.01]3% improvementAll studies3%0.97 [0.94-1.00]3% improvement1 metformin COVID-19 hospitalization resultc19early.com/mf Oct 16, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.14Favors metforminFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)-15%1.15 [0.73-1.83]hosp./ER32/21727/206Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-15%1.15 [0.73-1.83]32/21727/206-15% improvementLuo75%0.25 [0.07-0.84]death3/10422/179Improvement, RR [CI]TreatmentControlWang58%0.42 [0.01-1.98]death1/913/49Chen33%0.67 [0.20-1.78]death4/4315/77Bramante7%0.93 [0.81-1.06]death394/2,333791/3,923Crouse61%0.39 [0.16-0.87]death8/7634/144Wander15%0.85 [0.80-0.90]deathTau​2 = 0.01; I​2 = 56.6%PrEP17%0.83 [0.71-0.97]410/2,565875/4,37217% improvementAll studies15%0.85 [0.73-0.99]442/2,782902/4,57815% improvement7 metformin COVID-19 serious outcomesc19early.com/mf Oct 16, 2021Tau​2 = 0.01; I​2 = 53.7%; Z = 2.13Effect extraction pre-specifiedFavors metforminFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)4%0.96 [0.85-1.10]viral+217 (n)206 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment4%0.96 [0.85-1.10]0/2170/2064% improvementAll studies4%0.96 [0.84-1.09]0/2170/2064% improvement1 metformin COVID-19 viral clearance resultc19early.com/mf Oct 16, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.59Favors metforminFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)-15%1.15 [0.73-1.83]hosp./ER32/21727/206Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-15%1.15 [0.73-1.83]32/21727/206-15% improvementAll studies-15%1.15 [0.71-1.85]32/21727/206-15% improvement1 metformin COVID-19 Randomized Controlled Trialsc19early.com/mf Oct 16, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.58Effect extraction pre-specifiedFavors metforminFavors control 00.250.50.7511.251.51.752+Luo75%0.25 [0.07-0.84]death3/10422/179Improvement, RR [CI]TreatmentControlWang58%0.42 [0.01-1.98]death1/913/49Chen33%0.67 [0.20-1.78]death4/4315/77Bramante7%0.93 [0.81-1.06]death394/2,333791/3,923Crouse61%0.39 [0.16-0.87]death8/7634/144Wander15%0.85 [0.80-0.90]deathTau​2 = 0.01; I​2 = 56.6%PrEP17%0.83 [0.71-0.97]410/2,565875/4,37217% improvementAll studies17%0.83 [0.71-0.97]410/2,565875/4,37217% improvement6 metformin COVID-19 peer reviewed trialsc19early.com/mf Oct 16, 2021Tau​2 = 0.01; I​2 = 56.6%; Z = 2.38Effect extraction pre-specifiedFavors metforminFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)-15%1.15 [0.73-1.83]hosp./ER32/21727/206Improvement, RR [CI]TreatmentControlReis (DB RCT)-18%1.18 [0.74-1.89]hosp./ER217 (n)206 (n)Reis (DB RCT)4%0.96 [0.85-1.10]viral+217 (n)206 (n)Luo75%0.25 [0.07-0.84]death3/10422/179Wang58%0.42 [0.01-1.98]death1/913/49Chen33%0.67 [0.20-1.78]death4/4315/77Bramante7%0.93 [0.81-1.06]death394/2,333791/3,923Bramante24%0.76 [0.60-0.96]death1,129 (n)2,173 (n)Bramante4%0.96 [0.82-1.14]death1,204 (n)1,750 (n)Crouse61%0.39 [0.16-0.87]death8/7634/144Wander15%0.85 [0.80-0.90]deathWander2%0.98 [0.92-1.06]ICUWander3%0.97 [0.94-1.01]hosp.metformin COVID-19 outcomesc19early.com/mf Oct 16, 2021Favors metforminFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit